{
    "organizations": [],
    "uuid": "48dbb03dd6f0e43aab0a3a5bcbd5bab0a3d981c5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-verona-pharma-says-positive-top-li/brief-verona-pharma-says-positive-top-line-data-from-phase-2a-trial-with-rpl554-idUSFWN1QK08S",
    "ord_in_thread": 0,
    "title": "BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2A Trial With Rpl554",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2 (Reuters) - Verona Pharma Plc:\n* ‍REG-VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2A TRIAL WITH RPL554 IN CYSTIC FIBROSIS PATIENTS​\n* ‍AWAIT RESULTS OF ONGOING PHASE 2B TRIAL FOR MAINTENANCE TREATMENT OF COPD, ANTICIPATE REPORTING TOP-LINE DATA EARLY IN Q2 OF 2018​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-03-02T15:43:00.000+02:00",
    "crawled": "2018-03-03T17:20:30.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "verona",
        "pharma",
        "plc",
        "pharma",
        "report",
        "positive",
        "data",
        "phase",
        "2a",
        "trial",
        "rpl554",
        "cystic",
        "fibrosis",
        "result",
        "ongoing",
        "phase",
        "2b",
        "trial",
        "maintenance",
        "treatment",
        "copd",
        "anticipate",
        "reporting",
        "data",
        "early",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}